{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:49:36Z","timestamp":1773798576702,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Cancer Research","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]},{"DOI":"10.13039\/501100003243","name":"European Union","doi-asserted-by":"publisher","award":["NU22-08-00148"],"award-info":[{"award-number":["NU22-08-00148"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Polymers"],"abstract":"<jats:p>High-dose therapy with cytarabine (araC) is a standard treatment for aggressive non-Hodgkin lymphomas, but its efficacy is limited by rapid enzymatic degradation. To overcome this, araC was conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers to form linear and star-like nanomedicines using six different spacers: 3-aminopropanoyl, 5-pentanoyl, 6-aminohexanoyl, 4-aminobenzoyl, glycyl, and diglycyl. The conjugates contained 12.5\u201314.7 wt% araC and exhibited distinct hydrolytic release profiles at pH 7.4. LC1 (3-aminopropanoyl) and LC6 (diglycyl) released the drug most rapidly (~80% bound after 72 h), and LC2, LC3, and the star conjugate SC1 showed intermediate stability (~90%), while LC4 (4-aminobenzoyl) was most stable (~95%). In vivo, all conjugates markedly suppressed tumor growth in patient-derived xenograft models of mantle cell and Burkitt lymphoma compared with free araC. LC1 and LC2 provided the most durable tumor control, delaying regrowth beyond 40 days, and SC1 achieved comparable efficacy at a reduced araC-equivalent dose (2 mg\/mouse vs. 3 mg\/mouse for linear conjugates). These results demonstrate that spacer structure critically influences drug release and identify LC1 and LC2 as promising candidates for further development in lymphoma therapy.<\/jats:p>","DOI":"10.3390\/polym17212837","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:31:58Z","timestamp":1761550318000},"page":"2837","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nanomedicines for Delivery of Cytarabine: Effect of Carrier Structure and Spacer on the Anti-Lymphoma Efficacy"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-2016","authenticated-orcid":false,"given":"Robert","family":"Pola","sequence":"first","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsk\u00e9ho n\u00e1m. 2, 162 00 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3877-002X","authenticated-orcid":false,"given":"Eli\u0161ka","family":"Grosmanov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsk\u00e9ho n\u00e1m. 2, 162 00 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-1801","authenticated-orcid":false,"given":"Michal","family":"Pechar","sequence":"additional","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsk\u00e9ho n\u00e1m. 2, 162 00 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-1855","authenticated-orcid":false,"given":"Libor","family":"Kostka","sequence":"additional","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsk\u00e9ho n\u00e1m. 2, 162 00 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Pokorn\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, U Nemocnice 5, 128 53 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Tu\u0161kov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, U Nemocnice 5, 128 53 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, U Nemocnice 5, 128 53 Prague, Czech Republic"},{"name":"First Department of Internal Medicine, Charles University General Hospital in Prague, Czech Republic, U Nemocnice 2, 128 08 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5908-5182","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Etrych","sequence":"additional","affiliation":[{"name":"Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsk\u00e9ho n\u00e1m. 2, 162 00 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2174\/1389450043345443","article-title":"Molecular targeting of drug delivery systems to cancer","volume":"5","author":"Minko","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10611860500065187","article-title":"Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck","volume":"13","author":"Nan","year":"2005","journal-title":"J. Drug Target."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2011.06.015","article-title":"Ulbrich. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy","volume":"154","author":"Etrych","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pechar, M., Pola, R., Studenovsk\u00fd, M., Bl\u00e1hov\u00e1, M., Grosmanov\u00e1, E., Dydowiczov\u00e1, A., Filipov\u00e1, M., Islam, R., Gao, S., and Fang, J. (2022). Polymer nanomedicines with enzymatically triggered activation: A comparative study of in vitro and in vivo anti-cancer efficacy related to the spacer structure. Nanomed. Nanotechnol. Biol. Med., 46.","DOI":"10.1016\/j.nano.2022.102597"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jconrel.2012.12.009","article-title":"Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel","volume":"166","author":"Zhang","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ejps.2010.07.014","article-title":"Synthesis, characterization, and in vivo evaluation of poly(ethylene oxide-co-glycidol)-platinate conjugate","volume":"41","author":"Zhou","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/088391159701200401","article-title":"Cytotoxicity and anticancer activity of macromolecular prodrugs of 5-fluorouracil","volume":"12","author":"Nichifor","year":"1997","journal-title":"J. Bioact. Compat. Polym."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Takemoto, H., Inaba, T., Nomoto, T., Matsui, M., Liu, X., Toyoda, M., Honda, Y., Taniwaki, K., Yamada, N., and Kim, J. (2020). Polymeric modification of gemcitabine via cyclic acetal linkage for enhanced anticancer potency with negligible side effects. Biomaterials, 235.","DOI":"10.1016\/j.biomaterials.2020.119804"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.addr.2020.07.020","article-title":"Polymer nanomedicines","volume":"156","author":"Yang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1983.1.11.689","article-title":"High-dose cytosine arabinoside in non-Hodgkin\u2019s lymphoma","volume":"1","author":"Kantarjian","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/pgs.11.149","article-title":"Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia","volume":"13","author":"Abraham","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_12","first-page":"495","article-title":"Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: A retrospective case series","volume":"108","author":"Chamberlain","year":"2012","journal-title":"J. Neuro-Oncology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11060-010-0435-y","article-title":"Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma","volume":"103","author":"Ostermann","year":"2011","journal-title":"J. Neuro-Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Salehi, B., Selamoglu, Z., Mileski, K.S., Pezzani, R., Redaelli, M., Cho, W.C., Kobarfard, F., Rajabi, S., Martorell, M., and Kumar, P. (2019). Liposomal cytarabine as cancer therapy: From chemistry to clinical applications. Biomolecules, 9.","DOI":"10.3390\/biom9120773"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/17425247.2010.527330","article-title":"Development of cytarabine prodrugs and delivery systems for leukemia treatment","volume":"7","author":"Chhikara","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molliq.2017.12.086","article-title":"Self-assembling nanoparticles based on cytarabine prodrugs: Synthesis, characterization and antitumor evaluation","volume":"251","author":"Liu","year":"2018","journal-title":"J. Mol. Liq."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.actbio.2020.11.014","article-title":"Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma","volume":"119","author":"Pola","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(99)00141-8","article-title":"Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation","volume":"64","author":"Ulbrich","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1021\/bm3019592","article-title":"Polymer Therapeutics with a Coiled Coil Motif Targeted against Murine BCL1 Leukemia","volume":"14","author":"Pola","year":"2013","journal-title":"Biomacromolecules"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.33549\/physiolres.933424","article-title":"Etrych. The pH-Dependent and Enzymatic Release of Cytarabine From Hydrophilic Polymer Conjugates","volume":"65","author":"Pola","year":"2016","journal-title":"Physiol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1021\/ma047611m","article-title":"Reversible Addition\u2212Fragmentation Chain Transfer Polymerization: End Group Modification for Functionalized Polymers and Chain Transfer Agent Recovery","volume":"38","author":"Perrier","year":"2005","journal-title":"Macromolecules"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113876","DOI":"10.1016\/j.jconrel.2025.113876","article-title":"Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas","volume":"384","author":"Manakov","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41374-022-00784-w","article-title":"Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas","volume":"102","author":"Kazantsev","year":"2022","journal-title":"Lab. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/BF01717434","article-title":"Leucinaminopeptidase-(Arylamidase-) Aktivit\u00e4t im Serum: Bestimmung mit Leucin-p-nitroanilid als Substrat","volume":"45","author":"Willig","year":"1967","journal-title":"Klin. Wochenschr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: Have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10662","DOI":"10.3390\/ijms221910662","article-title":"Butyrylcholinesterase\u2013Protein Interactions in Human Serum","volume":"22","author":"Jasiecki","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Polymers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4360\/17\/21\/2837\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:38:31Z","timestamp":1761550711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4360\/17\/21\/2837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":26,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["polym17212837"],"URL":"https:\/\/doi.org\/10.3390\/polym17212837","relation":{},"ISSN":["2073-4360"],"issn-type":[{"value":"2073-4360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}